ИНСУЛИНРЕЗИСТЕНТЛИКНИНГ ИШЕМИК ИНСУЛЬТ ПАТОГЕНЕЗИ ВА ПРОГНОЗИДАГИ АҲАМИЯТИ
##article.subject##:
инсулинрезистентлик, ишемик инсульт, HOMA-IR, TyG индекси, эндотелиал дисфункция, нейрояллиғланиш, оксидатив стресс, атеросклероз, биомаркерлар##article.abstract##
Ишемик инсульт замонавий тиббиётнинг энг долзарб муаммоларидан бири бўлиб, ўлим ва узоқ муддатли ногиронликнинг етакчи сабабларидан ҳисобланади. Артериал гипертензия, қандли диабет, дислипидемия ва семизлик каби анъанавий хавф омиллари билан бир қаторда, сўнгги йилларда инсулинрезистентликнинг цереброваскуляр касалликлар ривожланишидаги аҳамиятига алоҳида эътибор қаратилмоқда. Инсулинрезистентлик нафақат глюкоза алмашинувининг бузилиши, балки эндотелиал дисфункция, атеросклероз, тромбоцитлар гиперреактивлиги, сурункали яллиғланиш, оксидатив стресс ва гематоэнцефалик тўсиқ шикастланиши билан кечувчи мураккаб метаболик ҳолатдир. Ушбу механизмлар ишемик инсультнинг юзага келиши ва оғир кечишига, шунингдек, инсультдан кейинги функционал тикланиш ва такрорий цереброваскуляр ҳодисалар хавфига таъсир кўрсатиши мумкин. Мазкур мақолада инсулинрезистентликнинг ишемик инсульт патогенезидаги асосий молекуляр ва васкуляр механизмлари, уни баҳолашда қўлланиладиган биомаркерлар ҳамда касаллик прогнозидаги аҳамияти замонавий илмий маълумотлар асосида таҳлил қилинди.
Библиографические ссылки
GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820.
Wieberdink RG, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB, Ikram MA. Insulin resistance and the risk of stroke and stroke subtypes in the nondiabetic elderly. Am J Epidemiol. 2012;176(8):699–707.
Rundek T, Gardener H, Xu Q, Goldberg RB, Wright CB, Boden-Albala B, et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the Northern Manhattan Study. Arch Neurol.2010;67(10):1195–1200.
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223.
Maciejczyk M, Żebrowska E, Chabowski A. Insulin resistance and oxidative stress in the brain: What’s new? Int J Mol Sci. 2019;20(4):874.
Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Häring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96(4):1169–1209.
Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, et al. Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology. 2003;60(9):1447–1451.
Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord.2013;14(1):5–12.
Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009;297(3):E568–E577.
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888–1904.
Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev.2007;28(5):463–491.
Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17(1):20–33.
Zhou M, Zhou Y, Jing J, Wang M, Jin A, Cai X, et al. Insulin resistance and white matter microstructural abnormalities in nondiabetic adult: A population-based study. Int J Stroke. 2024;19(10):1162–1171.
Kelem A, Adane T, Shiferaw E. Insulin resistance-induced platelet hyperactivity and a potential biomarker role of platelet parameters: A narrative review. Diabetes Metab Syndr Obes. 2023;16:2843–2853.
Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G. Platelet activation in obesity and metabolic syndrome. Obes Rev. 2012;13(1):27–42.
Altalhi R, Pechlivani N, Ajjan RA. PAI-1 in diabetes: Pathophysiology and role as a therapeutic target. Int J Mol Sci. 2021;22(6):3170.
Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26(10):2200–2207.
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157–172.
Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep.2018;18(12):127.
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.
Lu YK, Dong J, Li YL, Liu YH, Hu LK, Chu X, et al. Association between insulin resistance and incidence of carotid atherosclerotic plaque: A cohort study. Nutr Metab Cardiovasc Dis. 2022;32(4):981–993.
Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–585.
Van Dyken P, Lacoste B. Impact of metabolic syndrome on neuroinflammation and the blood-brain barrier. Front Neurosci. 2018;12:930.
De Felice FG, Lourenco MV. Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease. Front Aging Neurosci. 2015;7:94.
Banks WA. The blood-brain barrier as an endocrine tissue. Nat Rev Endocrinol. 2019;15(8):444–455.
Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: From physiology to disease and back. Physiol Rev. 2019;99(1):21–78.
Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke.2011;42(11):3323–3328.
Maciejczyk M, Żebrowska E, Chabowski A. Insulin resistance and oxidative stress in the brain: What’s new? Int J Mol Sci. 2019;20(4):874.
Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50(5):567–575.
Jurcau A, Ardelean AI. Oxidative stress in ischemia/reperfusion injuries following acute ischemic stroke. Biomedicines. 2022;10(3):574.
Andrabi SS, Parvez S, Tabassum H. Ischemic stroke and mitochondria: mechanisms and targets. Protoplasma.2020;257(2):335–343.
Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Häring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96(4):1169–1209.
Pearson-Leary J, McNay EC. Intrahippocampal administration of amyloid-β1-42 oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. J Alzheimers Dis. 2012;30(2):413–422.
Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009;1296:35–45.
Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157–188.
Choi DW. Excitotoxicity: Still hammering the ischemic brain in 2020. Front Neurosci. 2020;14:579953.
Ding PF, Zhang HS, Wang J, Gao YY, Mao JN, Hang CH, Li W. Insulin resistance in ischemic stroke: Mechanisms and therapeutic approaches. Front Endocrinol (Lausanne). 2022;13:1092431.
Chang Y, Kim CK, Kim MK, Seo WK, Oh K. Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients. Sci Rep. 2021;11(1):1229.
Wang S, Ning X, Tu J, Wang J, Zhao Y. Triglyceride-glucose index as a predictor of one-year mortality in non-diabetic acute ischemic stroke. Front Endocrinol (Lausanne). 2025;16:1523787.
Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46(2):189–197.
Rakhimbaeva GS, Abdurakhmonova KBK. ICAM-1 and CRP as biomarkers of 3-month outcome in acute ischaemic stroke. BMJ Neurol Open. 2023;5(2):e000516.
Bustamante A, Simats A, Vilar-Bergua A, García-Berrocoso T, Montaner J. Blood/brain biomarkers of inflammation after stroke and their association with outcome: From C-reactive protein to damage-associated molecular patterns. Neurotherapeutics. 2016;13(4):671–684.
Pawluk H, Woźniak A, Grześk G, Kołodziejska R, Kozakiewicz M, Kopkowska E, et al. The role of selected pro-inflammatory cytokines in pathogenesis of ischemic stroke. Clin Interv Aging. 2020;15:469–484.
Rakhimbaeva GS, Abdurakhmonova KBK. ICAM-1 and CRP as biomarkers of 3-month outcome in acute ischaemic stroke. BMJ Neurol Open. 2023;5(2):e000516.
Puig N, Camps-Renom P, Camacho M, Aguilera-Simón A, Jiménez-Altayó F, Fernández-León A, et al. Plasma sICAM-1 as a biomarker of carotid plaque inflammation in patients with a recent ischemic stroke. Transl Stroke Res. 2022;13(5):745–756.
Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104(12):1336–1342.
Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Dávalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34(1):40–46.
Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107(4):598–603.
Jing J, Pan Y, Zhao X, Zheng H, Jia Q, Mi D, et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke: The ACROSS-China Study. Stroke. 2017;48(4):887–893.
Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, et al. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):e1470–e1477.
Rundek T, Gardener H, Xu Q, Goldberg RB, Wright CB, Boden-Albala B, et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the Northern Manhattan Study. Arch Neurol.2010;67(10):1195–1200.
Kaynak N, Kennel V, Rackoll T, Schulze D, Endres M, Nave AH. Impaired glucose metabolism and the risk of vascular events and mortality after ischemic stroke: A systematic review and meta-analysis. Cardiovasc Diabetol.2024;23(1):323.
Yang Y, Rosenberg GA. Matrix metalloproteinases as therapeutic targets for stroke. Brain Res. 2015;1623:30–38.
Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904–2909.
